SCHEMBL870205

SCHEMBL870205

O=c1c2ccc(F)cc2[nH]c2cc3c(=O)c4ccc(F)cc4[nH]c3cc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.65
ALDH1A1 P00352 4/20 0.65
GLA P06280 2/20 0.65
GAA P10253 2/20 0.65
HTT P42858 2/20 0.65
DAO P14920 1/20 0.52
FEN1 P39748 1/20 0.51
LMNA P02545 2/20 0.49
HPGD P15428 2/20 0.49
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
PARP1 P09874 1/20 0.46
KIF11 P52732 1/20 0.46
ATM Q13315 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CDC25A P30304 1/20 0.44
CDC25C P30307 1/20 0.44
CCNE2 O96020 1/20 0.44
CDK4 P11802 1/20 0.44
CCND1 P24385 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14668858 0.88 KDM4E (0.76) KDM4EALDH1A1GLAGAAHTT
SCHEMBL9708991 0.86 GAA (0.80) KDM4EALDH1A1GLAGAAHTT
SCHEMBL21327343 0.84 KIF11 (0.66) KDM4EALDH1A1GLAGAAHTT
SCHEMBL14598932 0.83 GAA (0.93) KDM4EALDH1A1GLAGAAHTT
SCHEMBL1517851 0.82 KIF11 (0.61) KDM4EALDH1A1GLAGAAHTT
SCHEMBL29507671 0.82 KIF11 (0.61) KDM4EALDH1A1GLAGAAHTT
SCHEMBL5444428 0.79 ALDH1A1 (1.00) KDM4EALDH1A1GLAGAAHTT
SCHEMBL14668859 0.78 KIF11 (0.68) KDM4EALDH1A1GLAGAAHTT
SCHEMBL12075227 0.77 KDM4E (0.57) KDM4EALDH1A1GLAGAAHTT
SCHEMBL276017 0.76 ALDH1A1 (0.65) KDM4EALDH1A1GLAGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3561876-B1 DISPLAY NOVALED GMBH (DE) 2022-02-16 EP disclosed
EP-3561876-A1 DISPLAY Novaled GmbH (DE) 2019-10-30 EP disclosed
US-10396293-B2 Electronic or optoelectronic device comprising an anchored thin molecular layer, process for its preparation and compound used therein NOVALED GMBH (DE) 2019-08-27 US disclosed
EP-2786435-B1 Compounds NOVALED GMBH (DE) 2019-07-17 EP disclosed
EP-2840622-B1 Electronic or optoelectronic device comprising an anchored thin molecular layer, process for its preparation and compound used therein NOVALED GMBH (DE) 2019-02-13 EP disclosed
US-9722183-B2 Display NOVALED GMBH (DE) 2017-08-01 US disclosed
US-20160211461-A1 Electronic or Optoelectronic Device Comprising an Anchored Thin Molecular Layer, Process for its Preparation and Compound Used Therein NOVALED GMBH (DE) 2016-07-21 US disclosed
EP-2840622-A1 Electronic or optoelectronic device comprising an anchored thin molecular layer, process for its preparation and compound used therein Novaled GmbH (DE) 2015-02-25 EP disclosed
US-20140332790-A1 Display NOVALED GMBH (DE) 2014-11-13 US disclosed
EP-2786435-A1 DISPLAY Novaled GmbH (DE) 2014-10-08 EP disclosed
US-8637858-B2 Tandem white OLED NOVALED AG (DE) 2014-01-28 US disclosed
WO-2013079217-A1 DISPLAY NOVALED AG (DE) 2013-06-06 WO disclosed
US-20120074392-A1 Tandem White OLED NOVALED AG (DE) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160211461-A1 Electronic or Optoelectronic Device Comprising an Anchored Thin Molecular Layer, Process for its Preparation and Compound Used Therein EPCAM, OR10J3, OR51E2 KDM4E 215/4885ALDH1A1 1046/4885GLA 4109/4885
US-10396293-B2 Electronic or optoelectronic device comprising an anchored thin molecular layer, process for its preparation and compound used therein EPCAM, OR10J3, OR51E2 KDM4E 215/4885ALDH1A1 1046/4885GLA 4109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.